ClinicalTrials.gg
CompletedNCT06122662ORIONUpdated Apr 30, 2026

AMX0035 and Progressive Supranuclear Palsy

A Phase 2/3 interventional study of AMX0035 and Placebo in Progressive Supranuclear Palsy, PSP and Neurodegenerative Diseases, sponsored by Amylyx Pharmaceuticals Inc.. Completed at 62 sites in 5 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Amylyx Pharmaceuticals Inc. · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Supranuclear Palsy, Progressive with a site in United States — 19 open to participants now, 25 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · United States.

Enrollment
18th of 52
139 · median 43
Started
2023
with 2 others
Phase 2/3
3 of 84
none open now
Registered
71st of 84
by date

Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, this one is the 18th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2023, is one of 3 in phase 2/3, and was the 71st registered.

Supranuclear Palsy, Progressive

171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.

Browse Supranuclear Palsy, Progressive studies →

Open to participants now

19 of the 84 studies in Supranuclear Palsy, Progressive with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Supranuclear Palsy, Progressive with a site in United States, or all of them as a file.
02

Study summary

A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.

Read the detailed description

AMX0035 is a fixed dose combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the endoplasmic reticulum (ER) and mitochondria. This clinical trial is designed to demonstrate that AMX0035 is safe and tolerable, and to assess its effect on disease progression as measured by the Progressive Supranuclear Palsy (PSP) Rating Scale (PSPRS) over a 52-week double-blind phase. The Phase 2b and Phase 3 study portions are planned to feature an identical design: a randomized, double-blind, placebo-controlled phase that is followed by an optional open-label extension (OLE) phase. The phase 3 portion of ORION may be initiated based on results of the phase 2b Interim Analysis and/or the Primary Analysis and the totality of data from the Phase 2b study portion.

03

Conditions studied

  • Progressive Supranuclear Palsy
  • PSP
  • Neurodegenerative Diseases
  • Atypical Parkinsonism

Keywords

  • Progressive Supranuclear Palsy
  • PSP
  • Steele-Richardson-Olszewski Syndrome
  • ORION
  • Amylyx
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 40 to 80 years of age, inclusive
  • Diagnosis of possible or probable PSP Richardson Syndrome
  • Presence of PSP symptoms for \<5 years
  • Score of \<40 on the total (28-item) Progressive Supranuclear Palsy Rating Scale (PSPRS)
  • Able to walk independently or with minimal assistance
  • Minimum score of 24 on the (MMSE)
  • Must reside outside a skilled nursing facility or dementia care facility at the time of screening. Residence in an assisted living facility is allowed
  • Must have a study partner willing to attend study visits and provide information on participant's status
  • Capable of providing
  • Capable and willing to comply with trial procedures including visits to the trial clinic, visit requirements and treatment schedule, including MRI scans
  • Female participants of must agree to use effective for the duration of the study and for 6 months after last dose of study drug.
  • Males must agree to use effective birth control method for the duration of the study and for 6 months after the last dose of study drug. Men must not plan to donate sperm.

Exclusion criteria

Exclusion Criteria:

  • Require use of a feeding tube
  • Evidence of any neurological disorder that could explain signs of PSP
  • Evidence of any neurological disorder other than PSP, including significant cerebrovascular abnormalities, vascular dementia, motor neuron disease or ALS, Huntington's disease, normal pressure hydrocephalus, brain tumor, seizure disorder, multiple sclerosis, or known structural brain abnormalities.
  • History of autosomal dominant PSP due to a Microtubule Associated Protein Tau (MAPT) mutation
  • History of an autosomal dominant mutation associated with Frontotemporal Lobar Degeneration (FTLD)
  • Prior or current diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
  • Presence of unstable psychiatric disease, cognitive impairment (e.g., major cognitive dysfunction), dementia, major depression, or substance abuse that would impair ability of the participant to provide and follow instructions
  • Abnormal liver function
  • Renal insufficiency
  • Ongoing anemia
  • History of Class III/IV heart failure per (NYHA)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    AMX0035

    AMX0035 administered by mouth for 52 weeks: once daily for first 2 weeks and then twice daily for remainder of study For participants electing to continue into the open-label phase at Week 52; AMX0035 will be administered once daily for first 2 weeks and then twice daily for remainder of open-label phase

    Drug: AMX0035

  • Placebo comparator
    Placebo

    Placebo administered by mouth for 52 weeks: once daily for first 2 weeks and then twice daily for remainder of study

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in total (28-item) Progressive Supranuclear Palsy Rating Scale (PSPRS) Score

    Assess the impact of AMX0035 on disease progression as measured by the Progressive Supranuclear Palsy (PSP) Rating Scale (PSPRS); Total scores range from 0-96 with higher scores indicating more progressed disease

    Time frame: 52 weeks

Secondary outcomes

  1. Change in total (10-item) Progressive Supranuclear Palsy Rating Scale (PSPRS) Score

    Assess the impact of AMX0035 on disease progression as measured by the Progressive Supranuclear Palsy (PSP) Rating Scale (PSPRS); Total scores range from 0-30 with higher scores indicating more progressed disease

    Time frame: 52 weeks

  2. Change in MDS-UPDRS Part II Score

    To evaluate the efficacy of AMX0035 on motor aspects of activities of daily living as measured on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-PDRS) Part II; Total scores range from 0-52 with lower scores indicating better function

    Time frame: 52 weeks

  3. Frequency of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Safety and tolerability of AMX0035 in participants with PSP

    Time frame: 52 weeks

07

Study locations

62 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Parkinson's & Movement Disorder Institute
    Fountain Valley, California 92708, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Stanford Movement Disorder Center
    Palo Alto, California 94304, United States
  • University of California, San Francisco (UCSF)
    San Francisco, California 94158, United States
  • UC Health Anschutz Outpatient Pavilion Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • UF Health Dorothy Mangurian Neuroimaging Suite
    Gainesville, Florida 32608, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Parkinsons and Movement Disorder Center at the Queens Medical Center
    Honolulu, Hawaii 96813, United States
  • Northwestern University PD and Movement Disorders Center
    Chicago, Illinois 60611, United States
  • University of Kansas Medical Center Research Institute, Inc.
    Kansas City, Kansas 66160, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536-0274, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Lahey Hospital and Medical Center
    Burlington, Massachusetts 01805, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • University of Minnesota, CTSI
    Minneapolis, Minnesota 55414, United States
  • Mayo Clinic - Rochester
    Rochester, Missouri 55905, United States
  • Cleveland Clinic Lou Ruvo Center for Brain Health
    Las Vegas, Nevada 89106, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Pennsylvania Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Veracity Neuroscience, LLC
    Memphis, Tennessee 38157, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Kerwin Medical Center
    Dallas, Texas 75231, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Central Texas Neurology Consultants
    Round Rock, Texas 78681, United States
  • University of Utah Movement Disorders Center
    Salt Lake City, Utah 84108, United States
  • Virginia Commonwealth University Department of Neurology
    Richmond, Virginia 23298-0059, United States
  • Hôpital de la Timone
    Marseille, Bouches-du-Rhône 13385, France
  • Hopital Caremeau
    Nîmes, Gard 30029, France
  • Groupe Hospitalier Pellegrin - Hôpital Pellegrin
    Bordeaux, Gironde 30076, France
  • CHU de Limoges - Hôpital Dupuytren
    Limoges, Haute Vienne 87042, France
  • CHU Rennes - Hopital Pontchaillou
    Rennes, Ille Et Vilaine 35033, France
  • Hopital Roger Salengro - CHU Lille
    Lille, Nord 59037, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, 75013, France
  • Universitaetsklinikum Duesseldorf AoeR
    Ulm, Baden-Wurttemberg 89081, Germany
  • Universitaetsklinikum Ulm
    Ulm, Baden-Wurttemberg 89081, Germany
  • Krankenhaus Agatharied
    Hausham, Bavaria 83734, Germany
  • Klinikum der Universität München
    Munich, Bavaria, Germany
  • Paracelsus-Elena-Klinik Kassel
    Kassel, Hesse 34128, Germany
  • Universitaetsklinikum Carl Gustav Carus TU Dresden
    Dresden, Saxony 1307, Germany
  • Asklepios Fachklinikum Stadtroda
    Stadtroda, Thuringia 7646, Germany
  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Milan, 20133, Italy
  • Azienda Ospedale-Università di Padova
    Padova, 35128, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, 168, Italy
  • Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza
    Roma, 185, Italy
  • Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi D'Aragona
    Salerno, 84131, Italy
  • Hospital de Cruces
    Barakaldo, Bizkaia 48903, Spain
  • Clinica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, València 46026, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 8036, Spain
  • Hospital Universitario de La Princesa
    Madrid, 28006, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, 41013, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Sep 2025, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Nov 8, 2023
StartActual
Dec 21, 2023
Primary completionActual
Sep 30, 2025
CompletionActual
Oct 21, 2025
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06122662
Lead sponsor
Amylyx Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Dec 21, 2023
Primary completion
Sep 30, 2025
Completion
Oct 21, 2025
Last update
Apr 30, 2026

Study contacts

Study Director
study director · Amylyx Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium phenylbutyrate and taurursodiol

Start the discussion